Chapter 15: Local Anesthetics — Module 4: Toxicity, Adverse Effects, and Special Populations Tier: Extended Clinical Cases (28 questions)
1. [CASE 1 — QUESTION 1]
A 58-year-old man with no significant comorbidities is undergoing an ultrasound-guided interscalene brachial plexus block with 30 mL of 0.5% bupivacaine in preparation for arthroscopic shoulder surgery. He is awake and lightly sedated, with standard monitors in place. About two-thirds of the way through the incremental injection, he reports a metallic taste, numbness around his lips, and ringing in both ears, and then becomes restless and anxious. What is the most appropriate immediate action?
A) Administer a 1 mg intravenous bolus of epinephrine and prepare to defibrillate
B) Continue the injection rapidly to complete the block before the symptoms intensify
C) Stop the injection immediately, call for help and lipid emulsion, secure the airway as needed, and prepare to treat seizures while monitoring closely for cardiovascular deterioration
D) Administer intravenous diphenhydramine and methylprednisolone for a presumed allergic reaction
E) Reassure the patient that these are expected sensations of a successful block and finish the injection
ANSWER: C
Rationale:
The metallic taste, circumoral numbness, tinnitus, and rising agitation are the classic early central nervous system prodrome of local anesthetic systemic toxicity (LAST). The correct immediate action is to stop injecting at once, summon help and lipid emulsion, secure the airway, and prepare to manage seizures while watching closely for cardiovascular signs. This prodromal window is precisely when stopping the drug can prevent progression to seizures and cardiovascular collapse.
Option A: Option A is incorrect because a standard 1 mg epinephrine bolus is specifically discouraged in LAST (reduced doses are used), and defibrillation is premature in a patient who has not arrested.
Option B: Option B is incorrect because continuing the injection delivers more drug and accelerates progression to severe toxicity.
Option D: Option D is incorrect because the prodrome reflects dose-dependent neurotoxicity, not an allergic reaction.
Option E: Option E is incorrect because these are warning signs of toxicity, not normal block sensations, and completing the injection would be dangerous.
2. [CASE 1 — QUESTION 2]
Continuing with the same patient, moments after the injection is stopped he develops a generalized tonic-clonic seizure. Which agent is most appropriate for terminating the seizure in this setting?
A) A benzodiazepine such as midazolam, because it controls the seizure while avoiding the added cardiac depression associated with propofol or thiopental
B) A large induction dose of propofol, because it is the most reliable seizure suppressant regardless of hemodynamic status
C) Succinylcholine, because abolishing the muscle activity terminates the underlying cortical seizure
D) Intravenous amiodarone, because it stabilizes both cardiac and cortical excitability
E) No pharmacologic treatment, because LAST seizures are harmless and self-limited
ANSWER: A
Rationale:
A benzodiazepine such as midazolam is preferred for terminating a LAST seizure because it controls seizure activity without adding the myocardial depression and negative inotropy associated with propofol or thiopental — an important consideration in a patient who may be progressing toward cardiovascular toxicity. If a benzodiazepine is unavailable, small doses of propofol are acceptable while lipid emulsion is prepared.
Option B: Option B is incorrect because a large propofol dose risks worsening cardiovascular depression in this vulnerable patient.
Option C: Option C is incorrect because a neuromuscular blocker only abolishes the visible muscle activity; it does not stop the underlying cortical seizure or protect the brain.
Option D: Option D is incorrect because amiodarone is to be avoided in LAST, where it adds further sodium and potassium channel blockade to compromised conduction.
Option E: Option E is incorrect because seizures cause hypoxia and metabolic stress and must be treated.
3. [CASE 1 — QUESTION 3]
Continuing with the same patient, despite seizure control he becomes hypotensive and develops a wide-complex ventricular dysrhythmia, then loses his pulse. Which combination of measures is most appropriate?
A) Standard ACLS with repeated 1 mg epinephrine boluses and amiodarone for the dysrhythmia
B) Vasopressin as the first-line vasopressor with high-dose epinephrine backup
C) Defibrillation alone, withholding all drugs until a perfusing rhythm returns
D) Intravenous lipid emulsion (1.5 mL/kg bolus then infusion) together with high-quality CPR, using reduced epinephrine doses and avoiding amiodarone and vasopressin
E) A calcium channel blocker to counteract the sodium channel blockade
ANSWER: D
Rationale:
This is bupivacaine-induced cardiovascular collapse, and management integrates the LAST-specific modifications. Intravenous lipid emulsion (1.5 mL/kg bolus followed by infusion) is the cornerstone and should be combined with high-quality CPR; epinephrine is given in reduced doses, and amiodarone and vasopressin are avoided.
Option A: Option A is incorrect because standard 1 mg epinephrine boluses can worsen arrhythmias in the poisoned myocardium and amiodarone adds further channel blockade to impaired conduction.
Option B: Option B is incorrect because vasopressin is specifically not recommended in LAST-related arrest.
Option C: Option C is incorrect because lipid emulsion should be given without delay rather than withholding drug therapy.
Option E: Option E is incorrect because routine calcium channel blockade is not part of LAST management and would not reverse the toxicity.
4. [CASE 1 — QUESTION 4]
Continuing with the same patient, after lipid emulsion and reduced-dose epinephrine he remains in a shockable rhythm that repeatedly recurs after each successful cardioversion. Which principle best guides ongoing management?
A) Resuscitation should be abandoned, since recurrent arrest after cardioversion indicates an unsurvivable injury
B) Bupivacaine dissociates slowly from cardiac sodium channels, so the channels re-block after each cardioversion; prolonged high-quality CPR should continue while lipid sequestration and redistribution reduce myocardial drug levels, and extracorporeal support (ECMO, the use of an external pump and oxygenator to maintain circulation) should be considered if available
C) The recurrence proves the diagnosis is not LAST, so lipid emulsion should be stopped
D) A single additional defibrillation will be definitive because the drug clears from the channels within seconds
E) High-dose vasopressin should now be added as the decisive intervention
ANSWER: B
Rationale:
Bupivacaine binds cardiac sodium channels with fast-in, slow-out kinetics, so even after successful cardioversion the channels rapidly re-block, producing recurrent arrest. The correct principle is to continue prolonged high-quality CPR — sometimes for 30 to 60 minutes or longer — while lipid sequestration and drug redistribution lower the myocardial concentration, and to consider extracorporeal support (ECMO) where available to maintain circulation in the interim.
Option A: Option A is incorrect because bupivacaine arrest is potentially survivable with prolonged effort and lipid therapy, so abandoning resuscitation is inappropriate.
Option C: Option C is incorrect because recurrent re-block after cardioversion is the expected behavior of bupivacaine toxicity, not evidence against it, and lipid emulsion should continue.
Option D: Option D is incorrect because it misstates the kinetics; slow dissociation is exactly why a single shock is not definitive.
Option E: Option E is incorrect because vasopressin is not recommended in LAST-related arrest.
5. [CASE 2 — QUESTION 1]
A 45-year-old healthy woman is scheduled for outpatient tumescent liposuction. The surgeon plans to infiltrate several liters of dilute lidocaine (0.05 to 0.1%) with epinephrine at 1:1,000,000, citing a maximum lidocaine dose of about 35 to 55 mg/kg for this technique — far above the conventional limits. What is the pharmacologic basis for this much higher allowable dose?
A) The dilute, epinephrine-containing solution infiltrated into the poorly vascular subcutaneous space is absorbed extraordinarily slowly, so peak plasma lidocaine levels stay low and are reached only many hours after injection
B) Lidocaine becomes pharmacologically inactivated when diluted below 0.1%
C) Subcutaneous fat metabolizes lidocaine locally before it can reach the circulation
D) The high total volume dilutes the patient's blood enough to keep the concentration subtoxic
E) Epinephrine chemically binds and neutralizes the lidocaine within the infiltrate
ANSWER: A
Rationale:
The Klein limit of roughly 35 to 55 mg/kg is far higher than conventional injection limits only because the tumescent technique combines extreme dilution, the poorly vascular subcutaneous injection site, and high-concentration epinephrine vasoconstriction to produce extraordinarily slow systemic absorption; peak plasma lidocaine may not be reached for 12 to 14 hours, and the peak stays below the toxic threshold when the technique is performed correctly.
Option B: Option B is incorrect because dilution lowers concentration but does not inactivate the drug pharmacologically.
Option C: Option C is incorrect because subcutaneous fat does not appreciably metabolize lidocaine; the slow absorption, not local metabolism, is protective.
Option D: Option D is incorrect because systemic blood dilution is not the mechanism; slow absorption from the depot is.
Option E: Option E is incorrect because epinephrine acts by vasoconstriction to slow absorption, not by chemically neutralizing the lidocaine.
6. [CASE 2 — QUESTION 2]
Continuing with the same patient, after infiltrating tumescent lidocaine at 35 mg/kg the surgeon proposes adding a peripheral nerve block with additional lidocaine for postoperative analgesia. What is the central safety concern?
A) None; the Klein limit already accounts for lidocaine given by any route, so the block is automatically safe
B) The block reduces total risk by distributing the drug across more tissue
C) Nerve block lidocaine is absorbed even more slowly than the tumescent infiltrate, so no concern arises
D) The tumescent lidocaine has fully cleared by this point, so the two doses cannot overlap
E) The Klein limit's safety depends on the uniquely slow absorption of the dilute, epinephrine-containing subcutaneous infiltrate; nerve block lidocaine is absorbed by a more vascular route on a faster timeline, so adding it pushes the patient beyond the pharmacokinetic model that justifies the high tumescent limit
ANSWER: E
Rationale:
The Klein limit applies specifically to the tumescent compartment, whose safety rests on extraordinarily slow absorption. Adding a peripheral nerve block introduces lidocaine absorbed by a more vascular route on a much faster timeline, so the combined exposure no longer fits the slow-absorption model, and the patient is pushed beyond the safety envelope the tumescent limit assumes.
Option A: Option A is incorrect because the Klein limit governs only the tumescent technique, not mixed routes.
Option B: Option B is incorrect because adding a faster-absorbed dose raises, not lowers, the combined peak risk.
Option C: Option C is incorrect because nerve block lidocaine is absorbed faster, not slower, than tumescent infiltrate.
Option D: Option D is incorrect because tumescent lidocaine peaks hours later and is still being absorbed when the block is placed, so the exposures overlap.
7. [CASE 2 — QUESTION 3]
Continuing with the same patient, in the recovery area about 30 minutes after the procedure she develops a racing, pounding heartbeat, fine tremor, and anxiety. She has no perioral numbness, no metallic taste, and no tinnitus. How should this be interpreted?
A) These findings are diagnostic of severe LAST, and lipid emulsion should be administered immediately without further assessment
B) These symptoms confirm a true allergic reaction to lidocaine
C) Tachycardia, tremor, and anxiety without sensory CNS symptoms are most consistent with the systemic effects of absorbed epinephrine and must be distinguished from early LAST, whose hallmark early signs are sensory (circumoral numbness, metallic taste, tinnitus); she warrants continued monitoring rather than reflexive antidote
D) These findings indicate methemoglobinemia and require methylene blue
E) The symptoms are meaningless and require no monitoring
ANSWER: C
Rationale:
Tachycardia, tremor, and anxiety are common sympathomimetic effects of systemically absorbed epinephrine from the tumescent solution, and the absence of the sensory CNS prodrome (circumoral numbness, metallic taste, tinnitus) argues against early LAST. The correct interpretation is to recognize the epinephrine effect while continuing to monitor, because the two can coexist and the delayed lidocaine peak still lies ahead.
Option A: Option A is incorrect because these adrenergic symptoms are not by themselves diagnostic of severe LAST, and reflexive lipid emulsion without assessment is inappropriate.
Option B: Option B is incorrect because tachycardia and tremor are sympathomimetic, not the urticaria, angioedema, or bronchospasm of true allergy.
Option D: Option D is incorrect because these findings are not the oxygen-resistant cyanosis of methemoglobinemia.
Option E: Option E is incorrect because the symptoms warrant continued monitoring given the delayed-absorption risk, even if presently benign.
8. [CASE 2 — QUESTION 4]
Continuing with the same patient, she is discharged 3 hours postoperatively. About 9 hours after the tumescent infiltration she has a witnessed generalized seizure at home and is brought back by ambulance. Which statement best explains this course and its prevention?
A) The late timing excludes local anesthetic toxicity, since LAST can only occur within minutes of injection
B) Tumescent lidocaine is absorbed so slowly that peak plasma levels can occur many hours after infiltration, so LAST may present after discharge; facilities should therefore extend post-procedure monitoring and ensure lipid emulsion and rescue resources are available, and high-risk patients should not be discharged before the absorption peak has safely passed
C) The seizure must be unrelated to the procedure because it occurred after discharge
D) The delayed onset proves the dose was within safe limits and requires no intervention
E) A late seizure indicates a true allergic reaction developing over hours
ANSWER: B
Rationale:
Because tumescent infiltrate is absorbed extremely slowly, peak plasma lidocaine may not occur until many hours after the procedure, so LAST can present in delayed fashion after discharge — a pattern fundamentally different from the immediate post-injection LAST of peripheral blocks. Prevention requires extended post-procedure monitoring, ready availability of lipid emulsion and rescue resources, and not discharging patients before the absorption peak has safely passed.
Option A: Option A is incorrect because delayed presentation is characteristic of the tumescent technique, not a reason to exclude LAST.
Option C: Option C is incorrect because discharge does not preclude evolving toxicity when the peak is delayed.
Option D: Option D is incorrect because an actual seizure requires management and does not indicate a safe dose.
Option E: Option E is incorrect because the CNS event reflects dose-dependent toxicity, not an allergic mechanism.
9. [CASE 3 — QUESTION 1]
A 62-year-old man receives a benzocaine spray to the oropharynx before an upper endoscopy. Within minutes he becomes visibly dusky and cyanotic. His pulse oximeter reads 85% and does not rise despite 100% oxygen by non-rebreather mask, yet he is hemodynamically stable and his arterial oxygen tension on a blood gas is high. What is the most appropriate diagnostic step?
A) Treat empirically for acute coronary syndrome and obtain serial troponins
B) Administer naloxone for presumed opioid-induced hypoventilation
C) Increase the oxygen flow rate and continue observation, expecting the saturation to normalize
D) Suspect methemoglobinemia from benzocaine and obtain co-oximetry, which directly measures the methemoglobin fraction, recognizing that a standard pulse oximeter plateaus near 85% and that the cyanosis is disproportionate to the high measured oxygen tension
E) Activate the massive transfusion protocol for presumed acute hemorrhage
ANSWER: D
Rationale:
Benzocaine is a classic cause of acquired methemoglobinemia. The hallmark presentation is central cyanosis unresponsive to oxygen, a pulse oximeter that plateaus near 85% regardless of severity, and cyanosis out of proportion to a high measured arterial oxygen tension. The correct diagnostic step is to suspect methemoglobinemia and obtain co-oximetry, which directly measures the methemoglobin fraction.
Option A: Option A is incorrect because the oxygen-resistant cyanosis with a fixed 85% reading points to methemoglobinemia, not coronary ischemia.
Option B: Option B is incorrect because there is no opioid exposure and naloxone does not affect methemoglobin.
Option C: Option C is incorrect because the saturation will not normalize with more oxygen, since the hemoglobin itself cannot carry oxygen.
Option E: Option E is incorrect because there is no evidence of hemorrhage; the picture is one of impaired oxygen carriage, not blood loss.
10. [CASE 3 — QUESTION 2]
Continuing with the same patient, co-oximetry confirms a methemoglobin fraction of 28%. Why does methemoglobinemia impair oxygen delivery more than an equivalent reduction in normal hemoglobin from simple anemia?
A) Methemoglobin cannot bind or carry oxygen (a functional anemia) AND it shifts the oxygen-hemoglobin dissociation curve of the remaining normal hemoglobin to the left, so that hemoglobin holds oxygen more tightly and releases less to the tissues
B) Methemoglobin binds oxygen more avidly and releases it normally, causing only mild impairment
C) Methemoglobin increases the total oxygen-carrying capacity while slowing the circulation
D) Methemoglobin has no effect on the remaining normal hemoglobin and only lowers the total count
E) Methemoglobin raises the dissolved oxygen tension in plasma, which masks the deficit
ANSWER: A
Rationale:
Methemoglobinemia impairs oxygen delivery by two combined mechanisms: the methemoglobin fraction cannot bind or transport oxygen (a functional anemia), and its presence shifts the oxygen-hemoglobin dissociation curve of the remaining normal hemoglobin to the left, so that hemoglobin releases less oxygen to the tissues. This dual effect makes methemoglobinemia more impairing than an equal drop in hemoglobin from simple anemia.
Option B: Option B is incorrect because methemoglobin cannot carry oxygen at all and the impairment is not mild.
Option C: Option C is incorrect because methemoglobin reduces, rather than increases, effective oxygen-carrying capacity.
Option D: Option D is incorrect because methemoglobin does affect the remaining hemoglobin by shifting its dissociation curve.
Option E: Option E is incorrect because methemoglobin does not raise plasma oxygen tension or mask the deficit; the dissolved tension can be high while delivery fails.
11. [CASE 3 — QUESTION 3]
Continuing with the same patient, he is symptomatic and a decision is made to treat. What is the first-line therapy and its mechanism of action?
A) High-flow oxygen alone, which chemically reduces methemoglobin back to functional hemoglobin
B) Intravenous lipid emulsion, which binds and removes the oxidized hemoglobin
C) Immediate exchange transfusion as the routine first step for all symptomatic cases
D) Intravenous epinephrine, which restores oxygen-carrying capacity by raising perfusion pressure
E) Intravenous methylene blue (1 to 2 mg/kg), which is reduced via an NADPH-dependent system (using NADPH generated by the hexose monophosphate shunt) to leukomethylene blue, accelerating the enzymatic conversion of methemoglobin back to functional hemoglobin
ANSWER: E
Rationale:
First-line therapy for significant or symptomatic methemoglobinemia is intravenous methylene blue, 1 to 2 mg/kg over several minutes. Methylene blue is reduced — using NADPH generated by the hexose monophosphate shunt — to leukomethylene blue, which then donates electrons to accelerate the conversion of methemoglobin (Fe3+) back to functional hemoglobin (Fe2+), with cyanosis typically improving within 15 to 30 minutes.
Option A: Option A is incorrect because oxygen does not chemically reduce methemoglobin; the defect is the hemoglobin's inability to carry oxygen.
Option B: Option B is incorrect because lipid emulsion is the antidote for local anesthetic systemic toxicity, not for hemoglobin oxidation.
Option C: Option C is incorrect because exchange transfusion is reserved for severe or refractory cases or when methylene blue is contraindicated, not as routine first-line therapy.
Option D: Option D is incorrect because epinephrine raises perfusion pressure but does not reduce methemoglobin back to functional hemoglobin.
12. [CASE 3 — QUESTION 4]
Continuing with the same patient, he responds poorly to an initial dose of methylene blue, and review of his chart reveals previously documented glucose-6-phosphate dehydrogenase (G6PD) deficiency. What is the most appropriate next step?
A) Administer a second, larger dose of methylene blue to overcome the inadequate response
B) Continue methylene blue at the same dose and simply wait longer for an effect
C) Stop escalating methylene blue, because G6PD deficiency limits the NADPH required to activate it (and methylene blue is itself an oxidant that may worsen hemolysis); switch to ascorbic acid and, for severe or refractory disease, exchange transfusion, while supporting oxygenation
D) Withhold all further treatment, since the methemoglobinemia will resolve on its own regardless of severity
E) Administer high-flow oxygen alone, which will now reduce the methemoglobin
ANSWER: C
Rationale:
The poor response is explained by the newly recognized G6PD deficiency: methylene blue must be reduced using NADPH from the hexose monophosphate shunt, which G6PD-deficient patients cannot adequately supply, so the drug is ineffective and, being an oxidant itself, may precipitate hemolysis. The correct step is to stop escalating methylene blue and switch to ascorbic acid, reserving exchange transfusion for severe or refractory disease, while supporting oxygenation.
Option A: Option A is incorrect because a larger methylene blue dose cannot overcome the lack of NADPH-dependent activation and raises oxidant risk.
Option B: Option B is incorrect because continued methylene blue will remain ineffective in G6PD deficiency.
Option D: Option D is incorrect because symptomatic methemoglobinemia is dangerous and requires active treatment.
Option E: Option E is incorrect because supplemental oxygen alone does not reduce methemoglobin back to functional hemoglobin.
13. [CASE 4 — QUESTION 1]
A 31-year-old woman at 39 weeks gestation with a history of mild chronic liver disease requests labor epidural analgesia and is later expected to need a continuous postpartum infusion for an operative repair. The anesthesiologist plans the initial epidural dose. Compared with a non-pregnant adult, how should the neuraxial dose be adjusted, and why?
A) Increase the dose, because pregnancy expands the epidural space and more drug is needed for adequate spread
B) Reduce the dose, because the engorged epidural venous plexus reduces subarachnoid and epidural space volume and increases cephalad spread for a given dose, while reduced protein binding from dilutional hypoproteinemia raises the free fraction, together heightening the risk of a high block and systemic toxicity
C) Keep the dose identical to a non-pregnant adult, since pregnancy does not change local anesthetic distribution
D) Increase protein-bound drug delivery, since albumin rises in pregnancy and binds more anesthetic
E) Use a benzocaine-based epidural solution to reduce systemic toxicity
ANSWER: B
Rationale:
At term, aortocaval compression engorges the epidural venous plexus and reduces the volume of the epidural and subarachnoid spaces, so a given dose spreads more cephalad and risks a high block; concurrently, dilutional hypoproteinemia reduces protein binding and raises the free fraction, increasing systemic toxicity risk. The rational adjustment is careful dose reduction and titration.
Option A: Option A is incorrect because the neuraxial space is reduced, not expanded, so less drug is needed for a given spread.
Option C: Option C is incorrect because pregnancy substantially alters both distribution and binding.
Option D: Option D is incorrect because albumin falls in pregnancy, lowering binding and raising free drug.
Option E: Option E is incorrect because benzocaine is a topical agent associated with methemoglobinemia and is not used for epidural analgesia.
14. [CASE 4 — QUESTION 2]
Continuing with the same patient, she reports a convincing prior anaphylactic reaction (urticaria, wheezing, and hypotension) to procaine, an ester local anesthetic, during a dental procedure years ago. Which choice for her current and postpartum local anesthesia is most appropriate?
A) Another ester agent, since ester anesthetics do not cross-react with one another
B) A multidose amide vial containing methylparaben, which is always safe in ester-allergic patients
C) No local anesthetic at all, because the cross-class reaction risk is prohibitive
D) A single-dose, preservative-free amide anesthetic, because amides produce no para-aminobenzoic acid (PABA, the ester allergen) and do not cross-react with esters, and avoiding the preservative removes the structurally PABA-like methylparaben as a confounder
E) A higher dose of procaine preceded by antihistamines to induce tolerance
ANSWER: D
Rationale:
Esters are metabolized to PABA, the allergen responsible for true ester allergy, whereas amides produce no PABA and do not cross-react, making an amide the rational substitute; additionally, methylparaben — a preservative in some multidose vials — is structurally similar to PABA and can itself trigger reactions in PABA-sensitive patients. The optimal choice therefore avoids both the ester class and the PABA-like preservative by using a single-dose, preservative-free amide.
Option A: Option A is incorrect because ester agents share the PABA metabolite and do cross-react, so another ester is unsafe.
Option B: Option B is incorrect because the methylparaben preservative is precisely the PABA-like confounder to avoid.
Option C: Option C is incorrect because a safe alternative exists, so withholding anesthesia is unnecessary.
Option E: Option E is incorrect because re-exposing the patient to the offending allergen risks a more severe reaction and antihistamines do not reliably prevent true anaphylaxis.
15. [CASE 4 — QUESTION 3]
Continuing with the same patient, postpartum she requires a continuous epidural infusion of an amide local anesthetic over several days, and her liver disease is now characterized as Child-Pugh class B. How should the amide infusion be managed?
A) Reduce the amide dose and infusion rate (commonly by 25 to 50%) and monitor for early toxicity, recognizing that impaired hepatic metabolism and reduced hepatic blood flow lower clearance and promote accumulation during continuous dosing, while reduced albumin further raises the free fraction
B) Use a standard adult amide infusion rate, since hepatic disease does not affect amide clearance
C) Increase the amide infusion rate to compensate for accelerated clearance in liver disease
D) Discontinue all neuraxial analgesia, because amide anesthetics are absolutely contraindicated in any hepatic impairment
E) Switch to a continuous benzocaine infusion to bypass hepatic metabolism
ANSWER: A
Rationale:
Amide local anesthetics depend on hepatic metabolism, and Child-Pugh class B disease reduces clearance through both impaired enzyme capacity and reduced hepatic blood flow, prolonging half-life and promoting accumulation during continuous infusion; reduced albumin further raises the free fraction. The appropriate management is to reduce the amide dose and infusion rate (commonly 25 to 50%) and monitor for early toxicity.
Option B: Option B is incorrect because hepatic disease clearly reduces amide clearance.
Option C: Option C is incorrect because clearance is reduced, not accelerated, so a higher rate would worsen accumulation.
Option D: Option D is incorrect because amides are not absolutely contraindicated in hepatic impairment; they require dose reduction and monitoring.
Option E: Option E is incorrect because benzocaine is a topical agent associated with methemoglobinemia and is not given as a continuous epidural infusion.
16. [CASE 4 — QUESTION 4]
Continuing with the same patient, for a subsequent minor procedure she receives hyperbaric lidocaine 5% spinal anesthesia in the lithotomy position. About 16 hours later she reports aching pain in both buttocks radiating to the posterior thighs, but her strength, sensation, and bowel and bladder function are entirely normal. What is the most likely diagnosis and appropriate management?
A) Cauda equina syndrome; obtain emergent MRI and neurosurgical consultation for decompression
B) Epidural hematoma; reverse any anticoagulation and image emergently
C) Spinal epidural abscess; begin empiric antibiotics and obtain urgent imaging
D) Anterior spinal artery syndrome; begin blood pressure augmentation
E) Transient neurologic symptoms (TNS); manage with NSAIDs and reassurance, expecting spontaneous resolution within about 72 hours without permanent deficit, while remaining alert for any objective neurologic deficit that would suggest a more serious process
ANSWER: E
Rationale:
Bilateral buttock and posterior-thigh pain beginning within 6 to 24 hours of spinal anesthesia with an entirely normal neurologic examination is the classic presentation of transient neurologic symptoms (TNS), which is most frequent after intrathecal hyperbaric lidocaine 5%, especially in the lithotomy position. TNS is self-limited, resolving within about 72 hours without permanent deficit, and is managed with NSAIDs and reassurance.
Option A: Option A is incorrect because cauda equina syndrome produces objective deficits such as saddle anesthesia and bowel or bladder dysfunction, which are absent here.
Option B: Option B is incorrect because an epidural hematoma typically causes progressive objective deficits rather than isolated pain with a normal exam.
Option C: Option C is incorrect because a spinal abscess usually presents with fever, back pain, and evolving deficits over days.
Option D: Option D is incorrect because anterior spinal artery syndrome causes motor and sensory deficits, not isolated self-limited pain with intact function.
17. [CASE 5 — QUESTION 1]
A 67-year-old man on maintenance hemodialysis is scheduled for a procedure and will receive regional anesthesia. The team is deciding between a single-shot peripheral nerve block and a continuous perineural catheter infusion of an amide local anesthetic. Regarding the effect of his renal failure, which statement is most accurate?
A) Renal failure markedly impairs metabolism of the parent amide, so even a single-shot block is dangerous and should be avoided
B) Renal failure increases protein binding, so all amide techniques are safer than in patients with normal renal function
C) For a single-shot block, dose adjustment is generally not required because amides are cleared hepatically, but renal failure becomes clinically relevant during continuous infusions, where accumulation of renally cleared active metabolites and altered protein binding raise toxicity risk
D) Renal failure has no bearing on local anesthetic management under any circumstances
E) Ester agents must be avoided in renal failure because their water-soluble metabolites accumulate dangerously
ANSWER: C
Rationale:
Amide local anesthetics are cleared by hepatic metabolism, so renal failure does not directly impair elimination of the parent drug, and for a single-shot peripheral block or single-dose neuraxial anesthetic, dose adjustment is generally not required. Renal failure becomes clinically relevant during continuous infusions or repeated dosing, where renally cleared active metabolites accumulate and concurrent hypoalbuminemia raises the free fraction.
Option A: Option A is incorrect because the parent amide is hepatically cleared, so a single-shot block is not contraindicated by renal failure.
Option B: Option B is incorrect because renal failure tends to reduce binding and raise the free fraction, not increase binding.
Option D: Option D is incorrect because renal failure does affect continuous-infusion management even if single-shot dosing is generally unaffected.
Option E: Option E is incorrect because ester metabolites are water-soluble and excreted without pharmacologic consequence in renal insufficiency, so esters are not the problem.
18. [CASE 5 — QUESTION 2]
Continuing with the same patient, a continuous lidocaine perineural infusion is started, and after about 36 hours he develops CNS symptoms even though a measured parent lidocaine concentration appears acceptable. Which mechanism best explains this?
A) Lidocaine itself is renally cleared, so the parent drug level must actually be higher than measured
B) Active lidocaine metabolites such as monoethylglycinexylidide (MEGX, a metabolite retaining substantial pharmacologic activity) are cleared by the kidney and accumulate in renal failure during continuous infusion, contributing to CNS effects even when the parent concentration looks acceptable
C) Lidocaine metabolites are entirely inactive, so their accumulation cannot contribute to toxicity
D) Renal failure increases protein binding so much that the patient should be protected from any toxicity
E) The symptoms must be unrelated to lidocaine because the parent level is acceptable
ANSWER: B
Rationale:
Lidocaine is metabolized hepatically, but its metabolites — including monoethylglycinexylidide (MEGX), which retains a substantial fraction of lidocaine's pharmacologic activity — are cleared renally. In dialysis-dependent renal failure these active metabolites accumulate during a continuous infusion and contribute to CNS effects even when the parent concentration appears acceptable.
Option A: Option A is incorrect because lidocaine itself is hepatically cleared; it is the renally cleared metabolites that accumulate.
Option C: Option C is incorrect because key metabolites such as MEGX are pharmacologically active.
Option D: Option D is incorrect because renal failure tends to reduce binding and raise the free fraction, not protect the patient.
Option E: Option E is incorrect because an acceptable parent level does not exclude toxicity from accumulated active metabolites.
19. [CASE 5 — QUESTION 3]
Continuing with the same patient, his serum albumin is found to be low at 2.0 g/dL. How does this finding compound his risk during the lidocaine infusion?
A) Low albumin slows hepatic metabolism of lidocaine, raising the total concentration
B) Low albumin increases renal clearance of the parent drug, lowering toxicity risk
C) Low albumin has no effect on local anesthetic distribution or toxicity
D) Reduced albumin lowers protein binding, raising the unbound (free, pharmacologically active) fraction of lidocaine, so a total concentration that looks acceptable can correspond to a higher free concentration acting on the brain and heart, effectively lowering the toxic threshold
E) Reduced albumin increases protein binding and lowers the free fraction, which is protective
ANSWER: D
Rationale:
Only the unbound (free) fraction of local anesthetic is pharmacologically active. Hypoalbuminemia reduces protein binding and raises the free fraction, so a measured total concentration that appears acceptable can correspond to a dangerously high free concentration acting on cardiac and neural tissue, effectively lowering the toxic threshold and compounding the metabolite-accumulation risk already present in renal failure.
Option A: Option A is incorrect because albumin status changes binding, not the rate of hepatic metabolism.
Option B: Option B is incorrect because low albumin does not increase renal clearance of the parent drug.
Option C: Option C is incorrect because albumin directly modulates free-drug exposure and toxicity.
Option E: Option E is incorrect because it reverses the relationship; reduced albumin lowers binding and raises the free fraction.
20. [CASE 5 — QUESTION 4]
Continuing with the same patient, the team wishes to continue effective regional analgesia while minimizing further toxicity risk. Which management approach is most appropriate?
A) Use a reduced infusion rate, monitor closely for early CNS symptoms, and consider ropivacaine over bupivacaine given its somewhat lower intrinsic cardiotoxicity; for any infiltration component, an ester agent is essentially unaffected by renal function because its hydrolysis occurs in plasma and tissue and its metabolites are water-soluble
B) Maximize the infusion rate to ensure analgesia, since the parent level is acceptable
C) Switch to racemic bupivacaine at full dose because it accumulates less than ropivacaine in renal failure
D) Discontinue all regional analgesia, since continuous techniques are absolutely contraindicated in dialysis patients
E) Add a benzocaine infusion to reduce systemic amide exposure
ANSWER: A
Rationale:
The appropriate approach reduces the infusion rate, monitors for early CNS symptoms, and favors ropivacaine over bupivacaine given ropivacaine's somewhat lower intrinsic cardiotoxicity; for any infiltration component, an ester agent is essentially unaffected by renal function because hydrolysis occurs in plasma and tissue and the metabolites are water-soluble and excreted without pharmacologic consequence.
Option B: Option B is incorrect because maximizing the rate worsens metabolite and free-drug accumulation.
Option C: Option C is incorrect because racemic bupivacaine is more cardiotoxic and full dosing is unsafe here.
Option D: Option D is incorrect because continuous techniques are not absolutely contraindicated; they require reduced rates and monitoring.
Option E: Option E is incorrect because benzocaine is a topical agent associated with methemoglobinemia and is not given as an infusion.
21. [CASE 6 — QUESTION 1]
A 74-year-old man with heart failure (reduced ejection fraction), atrial fibrillation maintained on flecainide, and a baseline widened QRS-complex (the ventricular depolarization waveform, QRS) on his electrocardiogram is scheduled for a large-volume lower-extremity regional anesthetic. With respect to his reduced cardiac output, what is the principal pharmacokinetic concern?
A) Reduced cardiac output increases hepatic blood flow, accelerating amide clearance and lowering the risk of accumulation
B) Reduced cardiac output has no effect on amide local anesthetic disposition
C) Heart failure increases renal clearance of the parent amide, protecting against toxicity
D) Reduced cardiac output speeds systemic absorption so much that peak levels are always subtoxic
E) Reduced cardiac output decreases hepatic blood flow and therefore amide local anesthetic clearance, predisposing to drug accumulation with repeated or continuous dosing, and reduces the dilutional buffering that normally limits peak arterial concentrations after a bolus
ANSWER: E
Rationale:
The reduced cardiac output of heart failure decreases hepatic blood flow and thereby amide local anesthetic clearance, predisposing to accumulation with repeated or continuous dosing; it also reduces the dilutional buffering that normally limits peak arterial concentrations after a bolus injection. Both effects raise toxicity risk.
Option A: Option A is incorrect because reduced cardiac output decreases, not increases, hepatic blood flow and clearance.
Option B: Option B is incorrect because reduced cardiac output clearly affects amide disposition.
Option C: Option C is incorrect because amides are hepatically cleared and heart failure does not protect via renal clearance.
Option D: Option D is incorrect because reduced cardiac output does not render peaks uniformly subtoxic; if anything it impairs the buffering that limits peaks.
22. [CASE 6 — QUESTION 2]
Continuing with the same patient, why does his chronic flecainide therapy and baseline widened QRS heighten the cardiac risk of a large local anesthetic load?
A) Flecainide protects cardiac sodium channels from local anesthetic binding, so the combination is safer than either drug alone
B) Flecainide and local anesthetics act on entirely unrelated targets, so there is no additive risk
C) Both local anesthetics and flecainide (a Class I antiarrhythmic) block cardiac sodium channels, so their effects are additive; a patient with baseline conduction slowing (widened QRS) already has a reduced threshold for further conduction toxicity from a sodium-channel-blocking anesthetic load
D) The widened QRS reflects a potassium channel problem that local anesthetics cannot worsen
E) Flecainide accelerates clearance of local anesthetics, eliminating any concern
ANSWER: C
Rationale:
Local anesthetics produce cardiac toxicity by blocking the cardiac sodium channel, and flecainide, a Class I antiarrhythmic, blocks the same channel; their effects are additive. A patient with baseline conduction slowing — manifested as a widened QRS — already has a reduced threshold for further conduction toxicity, so a large sodium-channel-blocking anesthetic load is especially hazardous.
Option A: Option A is incorrect because flecainide adds to, rather than protects against, sodium-channel blockade.
Option B: Option B is incorrect because both agents converge on the cardiac sodium channel, making the risk additive.
Option D: Option D is incorrect because the widened QRS reflects slowed sodium-channel-dependent ventricular conduction, which local anesthetics can worsen.
Option E: Option E is incorrect because flecainide does not accelerate local anesthetic clearance.
23. [CASE 6 — QUESTION 3]
Continuing with the same patient, the anesthesiologist must select the local anesthetic for this large-volume block. Which choice and accompanying precautions are most rational?
A) Choose ropivacaine over racemic bupivacaine, because ropivacaine carries a lower risk of cardiovascular collapse for a given analgesic dose; use the lowest effective dose, fractionate the injection, and ensure lipid emulsion and resuscitation resources are immediately available
B) Choose racemic bupivacaine at a large volume, since it is the safest long-acting agent for cardiac patients
C) Choose racemic bupivacaine because it dissociates from cardiac sodium channels faster than ropivacaine
D) Choose any agent at maximal dose, since agent identity does not affect cardiac risk
E) Avoid all long-acting agents and use repeated high-dose boluses of a short-acting agent instead
ANSWER: A
Rationale:
In a patient with reduced cardiac output, conduction slowing, and concurrent sodium-channel-blocking therapy, the rational choice is the less cardiotoxic agent. Ropivacaine carries a lower risk of cardiovascular collapse for a given analgesic dose than racemic bupivacaine, so it is preferred, used at the lowest effective dose with fractionated injection and lipid emulsion and resuscitation resources ready.
Option B: Option B is incorrect because racemic bupivacaine is the most cardiotoxic option and a large volume compounds the risk.
Option C: Option C is incorrect because bupivacaine dissociates slowly, not faster, and is more cardiotoxic than ropivacaine.
Option D: Option D is incorrect because agent identity strongly affects cardiac risk.
Option E: Option E is incorrect because repeated high-dose boluses raise cumulative exposure and do not reduce risk.
24. [CASE 6 — QUESTION 4]
Continuing with the same patient, it is noted that he has an implanted cardioverter-defibrillator (ICD). Which consideration is most relevant to performing his regional anesthetic?
A) The ICD makes any regional technique absolutely contraindicated and the case must be cancelled
B) Electrical nerve stimulators used during block placement can generate electromagnetic noise that may affect the device, a concern largely obviated by using ultrasound guidance; in addition, if a high neuraxial sympathectomy causes significant bradycardia, the device's bradycardia-pacing function helps maintain cardiac output
C) The ICD eliminates any risk of local anesthetic cardiotoxicity, so standard high doses are safe
D) Local anesthetics permanently disable implanted cardiac devices and must never be used near them
E) The presence of an ICD means lipid emulsion is unnecessary because the device will treat any arrhythmia
ANSWER: B
Rationale:
Two device-related considerations are relevant. Electrical nerve stimulators used during block placement can generate electromagnetic noise that may interfere with an implanted device, a concern largely obviated by using ultrasound guidance instead. Separately, if a high neuraxial or thoracic sympathectomy produces significant bradycardia, the device's bradycardia-pacing function helps maintain cardiac output.
Option A: Option A is incorrect because an ICD does not absolutely contraindicate regional anesthesia; it prompts specific precautions.
Option C: Option C is incorrect because an ICD does not eliminate local anesthetic cardiotoxicity, so dose discipline remains essential.
Option D: Option D is incorrect because local anesthetics do not disable cardiac devices.
Option E: Option E is incorrect because lipid emulsion remains the essential antidote for LAST regardless of an ICD, which does not treat anesthetic-induced sodium channel blockade.
25. [CASE 7 — QUESTION 1]
A 36-year-old woman is referred for evaluation before a planned procedure because she reports being "allergic to local anesthetics." She recalls feeling faint and lightheaded during a dental injection on one occasion and having palpitations and anxiety on another, but she has never had a rash, swelling, or difficulty breathing. How should the clinician characterize the majority of such reported local anesthetic reactions?
A) The majority represent true IgE-mediated anaphylaxis and contraindicate all local anesthetics
B) The majority represent delayed T-cell-mediated contact dermatitis requiring patch testing
C) The majority represent toxic overdose from excessive injected volume
D) The majority of reactions attributed to local anesthetic allergy are not immunologic at all, but rather vasovagal episodes, epinephrine-mediated sympathomimetic effects, anxiety reactions, or toxic effects from systemic absorption, none of which involve IgE- or T-cell-mediated mechanisms
E) The majority represent true allergy to the amide class specifically
ANSWER: D
Rationale:
The vast majority of adverse reactions patients attribute to local anesthetic allergy are not immunologic; they represent vasovagal episodes, epinephrine-mediated sympathomimetic effects, anxiety reactions, or toxic effects from excessive systemic absorption. This characterization matters because it determines whether the patient can safely receive local anesthetics in the future. Her fainting and palpitations without urticaria, angioedema, or bronchospasm fit this non-immunologic pattern.
Option A: Option A is incorrect because true IgE-mediated anaphylaxis is the exception, not the majority, and does not describe her history.
Option B: Option B is incorrect because delayed contact dermatitis is a localized eczematous reaction to topical agents, not the typical reported reaction.
Option C: Option C is incorrect because toxic overdose is one mechanism but does not account for the majority, which are vasovagal or sympathomimetic.
Option E: Option E is incorrect because true amide allergy is extremely rare.
26. [CASE 7 — QUESTION 2]
Continuing with the same patient, suppose instead that her history clearly described true anaphylaxis (urticaria, bronchospasm, hypotension) following an ester local anesthetic. What is the appropriate management for her upcoming procedure?
A) Use an amide local anesthetic, because amides are not metabolized to para-aminobenzoic acid (PABA, the ester allergen) and do not cross-react with esters, so an amide can be substituted safely
B) Use a different ester agent, since esters do not cross-react with one another
C) Avoid all local anesthetics permanently and proceed without anesthesia
D) Re-administer the same ester agent at a lower dose to build tolerance
E) Pretreat with corticosteroids and give the same ester agent
ANSWER: A
Rationale:
A patient with a true allergic reaction to an ester agent should receive an amide. Esters are metabolized to PABA, the allergen responsible for the reaction; amides produce no PABA, and cross-reactivity between the two classes is not pharmacologically plausible, so an amide is a safe substitute.
Option B: Option B is incorrect because ester agents share the PABA metabolite and do cross-react, making another ester unsafe.
Option C: Option C is incorrect because a safe alternative class exists, so avoiding all local anesthetics is unnecessary.
Option D: Option D is incorrect because re-administering the offending allergen risks a more severe reaction rather than tolerance.
Option E: Option E is incorrect because corticosteroid pretreatment does not reliably prevent a true IgE-mediated reaction, and continuing the offending class is the wrong strategy when an amide is available.
27. [CASE 7 — QUESTION 3]
Continuing with the same patient, consider a different scenario in which she reacted to a multidose vial of an amide anesthetic, even though true amide allergy is very rare. What is the most likely explanation and the practical solution?
A) Amide anesthetics are metabolized to PABA, so the reaction proves a genuine amide allergy
B) The reaction confirms cross-reactivity between amides and esters at the receptor level
C) Amide vials spontaneously degrade into histamine, so the reaction is unavoidable with any amide preparation
D) The reaction proves an IgE-mediated amide allergy that contraindicates all local anesthetics for life
E) Methylparaben, a preservative in some multidose amide vials, is structurally similar to PABA and can trigger reactions in PABA-sensitive individuals; using a single-dose, preservative-free amide formulation removes the preservative as a confounder
ANSWER: E
Rationale:
Many reactions attributed to amide agents are actually due to methylparaben, a preservative in some multidose vials whose structure resembles PABA and can elicit reactions in PABA-sensitive individuals; the amide itself is usually not the culprit. The practical solution is to use a single-dose, preservative-free amide formulation, removing the preservative as a confounder.
Option A: Option A is incorrect because amide metabolism does not produce PABA.
Option B: Option B is incorrect because amides and esters do not cross-react at the receptor level.
Option C: Option C is incorrect because amides do not spontaneously degrade into histamine in the vial.
Option D: Option D is incorrect because such reactions rarely represent true amide allergy and do not justify lifelong avoidance of all local anesthetics.
28. [CASE 7 — QUESTION 4]
Continuing with the same patient, suppose her history is genuinely ambiguous and the class of agent involved cannot be determined. What is the most appropriate next step rather than simply avoiding all local anesthetics indefinitely?
A) Document a lifelong allergy to all local anesthetics and plan all future procedures under general anesthesia
B) Proceed with any local anesthetic without evaluation, since reactions are always benign
C) Refer for formal allergy evaluation with graded challenge testing performed by an allergist in a monitored setting, because indefinite avoidance of all local anesthetics carries its own risk (inadequately anesthetized procedures), and most patients can ultimately be shown to tolerate an appropriate agent
D) Empirically select an ester agent, since esters are the safest default in ambiguous cases
E) Treat her as confirmed anaphylactic and prescribe an epinephrine autoinjector for all future dental visits
ANSWER: C
Rationale:
When the history is ambiguous and the implicated class is unclear, the appropriate step is formal allergy evaluation with graded challenge testing by an allergist in a monitored setting, rather than avoiding all local anesthetics indefinitely; untreated or inadequately anesthetized procedures carry their own substantial risk, and most patients can be shown to tolerate an appropriate agent.
Option A: Option A is incorrect because indefinite blanket avoidance is not justified and imposes real harm.
Option B: Option B is incorrect because proceeding without any evaluation ignores a genuinely ambiguous history and the rare possibility of true allergy.
Option D: Option D is incorrect because esters are the class more likely to cause true allergy, so they are not a safe empiric default.
Option E: Option E is incorrect because treating an unconfirmed, ambiguous history as definite anaphylaxis is inappropriate and an autoinjector does not address the diagnostic question.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.